Background: Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder, typically characterized by anovulation, infertility, Hyperandrogenism, Insulin resistance and increased levels of anti-Müllerian hormone (AMH) .Met- formin has long been used in the treatment of polycystic ovary syndrome. Recently, it has been reported that empagliflozin can be effective in improving the symptoms of PCOS. Therefore, in this research, we decided to investigate the effects of met- formin and Empagliflozin on Antimullerin hormone levels in PCOS patients. Materials and Methods: Participants were randomly assigned to receive metformin, empagliflozin, and placebo. The treat- ment was performed 2 months before the start of the ovulation cycle and continued until the day of the puncture. Results: The serum level of Antimullerin Hormone (AMH) be- fore and after treatment showed a significant decrease in both metformin and empagliflozin groups, but this decrease was sig- nificant in the empagliflozin group (P=0.01) and not signifi- cant in the metformin group (P=0.08). Also, serum AMH level decreased after 2 months of drug use between metformin and empagliflozin treatment groups with placebo, and this decrease was significant in empagliflozin group. However, the AMH level of follicular fluid (FF) in metformin and empagliflozin group after 2 months of drug use was not significantly different compared to placebo (P=0.58). Conclusion: Therefore, it can be said that empagliflozin can perform better in reducing serum levels and modulating AMH in PCOS patients who have higher AMH compared to metform- in.
